Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders

Mohamed A. Chinnaratha, Uthayanan Chelvaratnam, Katherine A. Stuart, Simone I. Strasser, Geoffrey W. McCaughan, Paul Gow, Leon A. Adams, Alan J. Wigg, on behalf of the Australia and New Zealand Liver Transplant Clinical Study Group – 21 April 2014 – An increased liver disease burden has been reported for Aboriginal and Torres Strait Islanders (ATSIs) in Australia; however, few proceed to liver transplantation (LT).

Reply

Riad Salem, Michael Vouche, Ali Habib, Edward Kim, Kent T. Sato, Ryan Hickey, Robert Lewandowski – 19 April 2014

Iron‐induced oxidative rat liver injury after non–heart‐beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine

Xianwa Niu, Wen Hua Huang, Bastiaan De Boer, Luc Delriviere, Ling Jun Mou, Gary P. Jeffrey – 19 April 2014 – This study investigated iron‐induced injury after warm ischemia in a non–heart‐beating (NHB) rat liver model and the effects of deferoxamine (DFO). Livers from heart‐beating (HB) rats or rats that were NHB for 60 minutes were stored in University of Wisconsin solution for 5 hours at 4°C [cold storage (CS)] and then were subjected to 2 hours of machine reperfusion (MRP) at 37°C.

Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications

Anders Boyd, Joël Gozlan, Sarah Maylin, Constance Delaugerre, Gilles Peytavin, Pierre‐Marie Girard, Fabien Zoulim, Karine Lacombe – 19 April 2014 – Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear.

Subscribe to